Serviços O conteúdo desse portal pode ser acessível em Libras usando o VLibras

Zika Virus (ZIKV) Complications (R21 Clinical Trial Optional)/NIH

Escrito por NOGP/aip  em 6 de Fevereiro de 2019

Purpose

The purpose of this Funding Opportunity Announcement (FOA) PA-18-048 is to provide support for research on Zika virus (ZIKV) and its complications.

ZIKV is a single-stranded RNA virus of the Flaviviridae family. It is transmitted to humans primarily through the bites of infected Aedes mosquitos, though both perinatal/in utero and sexual transmission have been reported.  Initially discovered in 1947, it has been reported in the Americas since 2014, with a major outbreak in Brazil starting in 2015.  Disease is seen in about 20% of infected people and is usually self-limited.  However, an association between ZIKV infection in pregnant women and severe microcephaly in their babies has been very concerning. Additionally the virus has been found in blood, fueling growing concerns about the risk of transfusion-transmission with particular concern over severe outcomes in at risk transfusion recipient populations such as women who are pregnant.

Research Scope

The R21 activity code is intended to encourage new exploratory and developmental research projects. For example, such projects could assess the feasibility of a novel area of investigation or a new experimental system that has the potential to enhance health-related research. Another example could include the unique and innovative use of an existing methodology to explore a new scientific area. These studies may involve considerable risk but may lead to a breakthrough in a particular area, or to the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on a field of biomedical, behavioral, or clinical research.

Applications for R21 awards should describe projects distinct from those supported through the traditional R01 activity code. For example, long-term projects, or projects designed to increase knowledge in a well-established area, will not be considered for R21 awards. Applications submitted to this FOA should be exploratory and novel. These studies should break new ground or extend previous discoveries toward new directions or applications.

The participating NIH institutes are issuing this FOA to determine whether ZIKV infection causes microcephaly and other congenital abnormalities in babies and the potential rapid spread of ZIKV to the United States.

Award Budget: Direct costs are limited to $275,000 over an R21 two-year period, with no more than $200,000 in direct costs allowed in any single year.

Potential applicants are strongly encouraged to contact Scientific/Research staff before submitting an application to this FOA to determine whether or not the proposed work is within the intended scope of this program, whether requested rapid funding is likely to be available, and whether the idea should be considered for initial submission as a fully developed application. Inquiries not meeting the rapid guidelines will be guided to other grant mechanisms and to program contacts to discuss alternatives.

Agência

National Institutes of Health (NIH)

Prazo de inscrição

domingo, 16 de junho de 2019 às 16:59 (82 dias restantes)

Critérios de elegibilidade

Foreign Institutions

Non-domestic (non-U.S.) Entities (Foreign Institutions) are  eligible to apply.
Non-domestic (non-U.S.) components of U.S. Organizations are  eligible to apply.
Foreign components, as defined in the NIH Grants Policy Statementare  allowed.

Guidelines

Applicants are strongly encouraged to contact NIBIB Program staff (https://www.nibib.nih.gov/research-funding) or the Scientific/Research contact for this FOA for guidance in advance of submitting an application to ensure their proposed project is in compliance with new NIH human subjects research and clinical trials policies (https://grants.nih.gov/policy/clinical-trials.htm) and consistent with the types of clinical trial projects that NIBIB supports.

Required Application Instructions

It is critical that applicants follow the Research (R) Instructions in the SF424 (R&R) Application Guide, except where instructed to do otherwise (in this FOA or in a Notice from the NIH Guide for Grants and Contracts). Conformance to all requirements (both in the Application Guide and the FOA) is required and strictly enforced. Applicants must read and follow all application instructions in the Application Guide as well as any program-specific instructions noted in Section IV. When the program-specific instructions deviate from those in the Application Guide, follow the program-specific instructions. Applications that do not comply with these instructions may be delayed or not accepted for review.

How to Apply

There are several options available to submit your application through Grants.gov to NIH and Department of Health and Human Services partners. You must use one of these submission options to access the application forms for this opportunity.

  1. Use the NIH ASSIST system to prepare, submit and track your application online.
  2. Use an institutional system-to-system (S2S) solution to prepare and submit your application to Grants.gov and eRA Commons to track your application. Check with your institutional officials regarding availability.
  3. Use Grants.gov Workspace to prepare and submit your application and eRA Commons to track your application.

Fonte

https://grants.nih.gov/grants/guide/pa-files/PA-18-048.html#_Section_III._Eligibility

NewsletterNovidades Cidacs